ImaCor Receives CE Mark for ClariTEE® Probe and Zura™ System

GARDEN CITY, N.Y.--(BUSINESS WIRE)-- ImaCor, Inc., the developer of the first and only hemodynamic transesophageal echocardiography (HTEE™) management system, today announced that the ClariTEE® probe and Zura™ platform have received CE Mark certification, allowing for the commercialization of these solutions in Europe.

The ClariTEE is a revolutionary miniaturized TEE probe specifically designed for easy, available, and accurate hemodynamic assessment of high-acuity patients that uniquely remains indwelling for up to 72 hours. Current U.S. users of the ClariTEE and Zura - which has received 510(k) clearance from the U.S. Food and Drug Administration - include physicians at world-renowned academic medical centers such as Columbia New York-Presbyterian Hospital, Vanderbilt University Medical Center, Hospital of the University of Pennsylvania, and Barnes-Jewish Hospital.

“We welcome this opportunity to work with European clinicians who have already expressed substantial interest in using HTEE, the first technology that allows continuous availability of TEE in intensive care units,” said Scott L. Roth, M.D., Co-Founder and Chief Medical Officer of ImaCor. “Given the high level of ultrasound integration in European critical care, I expect HTEE to make a rapid and significant impact.”

“HTEE leads to optimal patient outcomes and appropriate resource utilization,” said Chad Wagner, M.D., the director of Vanderbilt University Medical Center's Cardiovascular Intensive Care Unit (CVICU). “Sharing HTEE technology with the European medical and scientific community will have a profound effect on future advances in this field.”

“Physicians throughout Europe are seeking the ImaCor system as a technologically advanced solution for addressing the burden of hemodynamic instability,” said Peter Pellerito, President and CEO of ImaCor. “Today, we are delighted to begin the process of making this solution available to them.”

About ImaCor

ImaCor, Inc. is a privately held company headquartered in Garden City, NY. The company designs, manufactures, and distributes advanced solutions for TEE monitoring in the critical care environment for the purpose of improving patient outcomes. ImaCor manufactures the ClariTEE® probe, the only miniaturized, indwelling probe suitable for long-term clinical settings. HTEE™, Zura™ and ClariTEE® are trademarks of ImaCor, Inc. For more information, please visit our website at www.imacormonitoring.com



CONTACT:

ImaCor, Inc.
Jennifer D. Kujawski
Director, Market Research & Public Relations
[email protected]
Phone: (516) 393.0970

KEYWORDS:   United States  Europe  North America  New York

INDUSTRY KEYWORDS:   Health  Cardiology  Hospitals  Medical Devices  Other Health  General Health

MEDIA:

Logo
 Logo

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.